Christiansen J V, Holm P, Reymann F, Thestrup-Pedersen K
Dermatologica. 1984;168(3):122-6.
From January 1976 to April 1982 etretinate was used to treat patients with morbus Darier (25 patients), pustulosis palmo-plantaris (72 patients), psoriasis (79 patients), and hyperkeratotic eczema of hands and feet (eczema keratoticum; 41 patients). Dosage of etretinate ranged between 0.5 and 1.0 mg/kg/day. In a retrospective survey at April 1, 1982, we observed a beneficial effect of the drug in all patients with morbus Darier, in 85% of patients with pustulosis palmo-plantaris, in 69% with psoriasis, and in 93% with eczema keratoticum. Many patients experienced side effects. Within 9 months more than half of the patients had stopped treatment primarily due to side effects, except patients with morbus Darier, whose median duration of treatment was 34 months with a range from 7 to 60 months. We will recommend that etretinate is used during short-term or intermittent courses of therapy, except in patients with morbus Darier, where a low dosage of etretinate is able to give a beneficial clinical effect.
1976年1月至1982年4月期间，依曲替酯被用于治疗 Darier病患者（25例）、掌跖脓疱病患者（72例）、银屑病患者（79例）以及手足角化过度性湿疹（角化性湿疹；41例）。依曲替酯的剂量为每日0.5至1.0毫克/千克。在1982年4月1日的一项回顾性调查中，我们观察到该药物对所有Darier病患者、85%的掌跖脓疱病患者、69%的银屑病患者以及93%的角化性湿疹患者有有益效果。许多患者出现了副作用。在9个月内，超过一半的患者主要因副作用而停止治疗，但Darier病患者除外，其治疗的中位持续时间为34个月，范围从7至60个月。我们建议，除了Darier病患者（低剂量依曲替酯即可产生有益的临床效果）外，依曲替酯应在短期或间歇性治疗过程中使用。
